Add like
Add dislike
Add to saved papers

CAPD: a successful treatment in patients suffering from therapy-resistant congestive heart failure.

During the last six years 13 patients suffering from congestive heart failure (CHF), refractory to conventional medical treatment and classified class IV as defined by the New York Heart Association (NYHA), were treated with continuous ambulatory peritoneal dialysis (CAPD) (1) at Innsbruck University Hospital, Department of Internal Medicine. All patients required intensive care and were end-stage. The minimum observation period was six weeks, maximum 67 months. Cardiac recompensation was effected in all patients, who were stabilized in class II after NYHA. The patient with the shortest observation period of six weeks received an orthotopic heart transplant. None of the patients died of a CAPD-associated complication. All patients were restored to a normal life style without major dependence on outside help. The occurrence and treatment of the prerenal kidney failure that causes life-threatening problems in end-stage CHF should be subject to further study with regard to its clinical course and the determination of plasma-ANF, plasma-renin and plasma-aldosterone concentration.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app